RESUMEN
Neuropathic pain remains prevalent and challenging to manage and is often comorbid with depression and anxiety. The new approach that simultaneously targets neuropathic pain and the associated comorbidities, such as depression and anxiety, is timely and critical, given the high prevalence and severity of neuropathic pain and the lack of effective analgesics. In this review, we focus on the animal models of neuropathic pain that researchers have used to investigate the analgesic effects of cannabidiol (CBD) and Beta-Caryophyllene (BCP) individually and in combination while addressing the impact of these compounds on the major comorbidity (e.g., depression, anxiety) associated with neuropathic pain. We also addressed the potential targets/mechanisms by which CBD and BCP produce analgesic effects in neuropathic pain models. The preclinical studies examined in this review support CBD and BCP individually and combined as potential alternative analgesics for neuropathic pain while showing beneficial effects on depression and anxiety.
Asunto(s)
Cannabidiol , Neuralgia , Animales , Neuralgia/tratamiento farmacológico , Sesquiterpenos Policíclicos , Analgésicos/farmacología , Analgésicos/uso terapéutico , Cannabidiol/farmacología , Cannabidiol/uso terapéutico , Receptores de CannabinoidesRESUMEN
Chronic pain, one of the most common reasons adults seek medical care, has been linked to restrictions in mobility and daily activities, dependence on opioids, anxiety, depression, sleep deprivation, and reduced quality of life. Alzheimer's disease (AD), a devastating neurodegenerative disorder (characterized by a progressive impairment of cognitive functions) in the elderly, is often co-morbid with chronic pain. AD is one of the most common neurodegenerative disorders in the aged population. The reported prevalence of chronic pain is 45.8% of the 50 million people with AD. As the population ages, the number of older people who experience AD and chronic pain will also increase. The current treatment options for chronic pain are limited, often ineffective, and have associated side effects. This review summarizes the role of the endocannabinoid system in pain, its potential role in chronic pain in AD, and addresses gaps and future directions.
Asunto(s)
Enfermedad de Alzheimer , Dolor Crónico , Anciano , Adulto , Humanos , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/epidemiología , Enfermedad de Alzheimer/tratamiento farmacológico , Dolor Crónico/epidemiología , Endocannabinoides/uso terapéutico , Calidad de Vida , Analgésicos OpioidesRESUMEN
Cannabis contains over 500 distinct compounds, which include cannabinoids, terpenoids, and flavonoids. However, very few of these compounds have been studied for their beneficial effects. There is an emerging concept that the constituents of the cannabis plant may work in concert to achieve better therapeutic benefits. This study is aimed at determining if the combination of a minor cannabinoid (cannabidiol, CBD) and a terpene (beta-caryophyllene, BCP) works in concert and if this has any therapeutic value. We used an inflammatory pain model (formalin) in mice to test for any functionality of CBD and BCP in combination. First, we determined the analgesic effect of CBD and BCP individually by establishing dose-response studies. Second, we tested the analgesic effect of fixed-ratio combinations and monitored any adverse effects. Finally, we determined the effect of this combination on inflammation. The combination of CBD and BCP produces a synergistic analgesic effect. This effect was without the cannabinoid receptor-1 side effects. The analgesic effect of CBD and BCP in combination involves an inflammatory mechanism. The combination of these two constituents of the cannabis plant, CBD and BCP, works in concert to produce a therapeutic effect with safety profiles through an inflammatory mechanism.
Asunto(s)
Cannabidiol , Cannabinoides , Cannabis , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Ratones , Animales , Cannabidiol/farmacología , Cannabidiol/uso terapéutico , Cannabinoides/farmacología , Cannabinoides/uso terapéutico , Sesquiterpenos Policíclicos/farmacología , Terpenos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/tratamiento farmacológico , Analgésicos/farmacología , Analgésicos/uso terapéutico , Dronabinol/uso terapéuticoRESUMEN
The brain mechanism of inflammatory pain is an understudied area of research, particularly concerning the descending pain modulatory system. The G protein-coupled receptor 55 (GPR55) is a lysophosphatidylinositol-sensitive receptor that has also been involved in cannabinoid signaling. It is widely expressed throughout the central nervous system, including the periaqueductal gray (PAG), a brainstem area and key element of the descending pain modulatory system. In this study, we used behavioral, stereotaxic injections, pharmacological tools, and two inflammatory pain models (formalin and carrageenan) to determine if GPR55 in the PAG plays a role in the pain associated with inflammation in rats. It was found that the blockade of GPR55 action in PAG can drive the descending pain modulatory system to mitigate inflammatory pain. These data show that GPR55 plays a role in the descending pain modulatory system in inflammatory pain.
Asunto(s)
Dolor , Sustancia Gris Periacueductal , Animales , Dolor/tratamiento farmacológico , Dimensión del Dolor , Sustancia Gris Periacueductal/metabolismo , Ratas , Receptores de Cannabinoides/metabolismo , Receptores Acoplados a Proteínas G/metabolismoRESUMEN
Despite successful virologic control with combination antiretroviral therapy (cART), about half of people living with the human immunodeficiency virus-1 (HIV) develop an HIV-associated neurocognitive disorder (HAND). It is estimated that 50% of individuals who are HIV-positive in the United States are aged 50 years or older. Therefore, a new challenge looms as individuals living with HIV increase in age. There is concern that Alzheimer's disease (AD) may become prevalent with an earlier onset of cognitive decline in people living with HIV (PLWH). Clinical data studies reported the presence of AD biomarkers in PLWH. However, the functional significance of the interaction between HIV or HIV viral proteins and AD biomarkers is still not well studied. The main goal of the present study is to address this knowledge gap by determining if the HIV envelope glycoprotein 120 (HIV-gp120) can affect the cognitive functions in the Tau mouse AD model. Male Tau and age-matched, wild-type (WT) control mice were treated intracerebroventricularly (ICV) with HIV-gp120. The animals were evaluated for cognitive function using a Y-maze. We found that HIV-gp120 altered cognitive function in Tau mice. Notably, HIV-gp120 was able to promote a cognitive decline in transgenic Tau (P301L) mice compared to the control (HIV-gp120 and WT). We provide the first in vivo evidence of a cognitive interaction between an HIV viral protein and Tau mice.
Asunto(s)
Enfermedad de Alzheimer , Disfunción Cognitiva , Infecciones por VIH , VIH-1 , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Antígenos Virales , Biomarcadores , Modelos Animales de Enfermedad , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , RatonesRESUMEN
There is a clear need for novel and improved therapeutic strategies for alleviating chronic neuropathic pain, as well as a need for better understanding of brain mechanisms of neuropathic pain, which are less understood than spinal and peripheral mechanisms. The G protein-coupled receptor 55 (GPR55), is a lysophosphatidylinositol (LPI)-sensitive receptor that has also been involved in cannabinoid signaling. It is expressed throughout the central nervous system, including the periaqueductal gray (PAG), a brainstem area and key element of the descending pain control system. Behaviors, pharmacology, biochemistry tools, and stereotaxic microinjections were used to determine if GPR55 plays a role in pain control in a chronic constriction injury (CCI) neuropathic pain model in rats. It was found that the blockade of GPR55 action in the PAG can restore and drive a descending control system to mitigate neuropathic pain. Our data demonstrate that GPR55 play a role in the descending pain control system, and identify GPR55 at supraspinal level as a neuropathic pain brain mechanism.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/farmacología , Dolor Crónico/metabolismo , Neuralgia/metabolismo , Sustancia Gris Periacueductal/metabolismo , Receptores de Cannabinoides/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Animales , Bencimidazoles/farmacología , Antagonistas de Receptores de Cannabinoides/administración & dosificación , Dolor Crónico/tratamiento farmacológico , Modelos Animales de Enfermedad , Masculino , Neuralgia/tratamiento farmacológico , Sustancia Gris Periacueductal/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores Acoplados a Proteínas G/antagonistas & inhibidoresAsunto(s)
Dolor Crónico/patología , Endocannabinoides/metabolismo , Infecciones por VIH/complicaciones , Neuralgia/patología , Receptores de Cannabinoides/metabolismo , Amidohidrolasas/metabolismo , Animales , Asialoglicoproteínas/metabolismo , Dolor Crónico/tratamiento farmacológico , Dolor Crónico/etiología , Modelos Animales de Enfermedad , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Proteína gp120 de Envoltorio del VIH/metabolismo , Infecciones por VIH/virología , VIH-1/metabolismo , Humanos , Lectinas Tipo C/metabolismo , Masculino , Marihuana Medicinal/farmacología , Marihuana Medicinal/uso terapéutico , Proteínas de la Membrana/metabolismo , Ratones , Neuralgia/tratamiento farmacológico , Neuralgia/etiología , Factores Sexuales , Asta Dorsal de la Médula Espinal/patologíaRESUMEN
Worldwide, women account for approximately 51% of human immunodeficiency virus-1 (HIV) seropositive individuals. The prevalence of neuropathic pain among individuals with HIV and a lack of preclinical data characterizing sex differences prompted us to address this knowledge gap. C57BL/6 male and female mice received multiple intrathecal injections of HIV-glycoprotein 120 (gp120), followed by determination of mechanical allodynia and thermal hypersensitivity for four weeks. The influence of ovarian hormones in the gp120 pain model was evaluated by comparison of ovariectomized (OVX) mice versus sham control. We found that gp120-induced neuropathic pain-like behaviors are sex-dependent. Female mice showed both increased mechanical allodynia and increased cold sensitivity relative to their male counterparts. The OVX mice showed reduced pain sensitivity compared to sham, suggesting a role of the ovarian hormones in sex differences in pain sensitivity to gp120. Gp120-induced neuropathic pain caused a shift in estrous cycle toward the estrus phase. However, there is a lack of clear correlation between the estrous cycle and the development of neuropathic pain-like behaviors during the four week recording period. This data provided the first evidence for sex differences in a rodent model of HIV-related neuropathic pain, along with a potential role of ovarian hormones.
Asunto(s)
Proteína gp120 de Envoltorio del VIH/metabolismo , Infecciones por VIH/complicaciones , VIH-1/aislamiento & purificación , Hiperalgesia/etiología , Neuralgia/etiología , Animales , Modelos Animales de Enfermedad , Femenino , Infecciones por VIH/virología , Humanos , Hiperalgesia/metabolismo , Hiperalgesia/virología , Masculino , Ratones Endogámicos C57BL , Neuralgia/metabolismo , Neuralgia/virología , Factores SexualesRESUMEN
The growing therapeutic use (self-medication) of cannabinoids by HIV-1 infected people and the recent interest in the possible medicinal use of cannabinoids, particularly in pain management, create an urgent need to identify their potential interactions with HIV-1. The goal here is to determine any interaction between proteins of HIV-1 and the analgesic effectiveness of cannabinoid at supraspinal level. Young adult male rats (Sprague-Dawley) were stereotaxically pretreated with HIV-1 envelope glycoprotein 120 (gp120) into the periaqueductal gray (PAG) area, the primary control center of pain modulation. Then, we examined its effect on cannabinoid receptor agonist WIN55,212-2-induced analgesia. Our results demonstrated that gp120 in PAG diminished the analgesic effectiveness of this cannabinoid agonist. These results suggest that gp120 may interact with the cannabinoid system through the descending modulatory pain pathways centered in the PAG to impair the analgesic effectiveness of cannabinoids.
Asunto(s)
Analgésicos/farmacología , Benzoxazinas/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Cannabinoides/farmacología , Proteína gp120 de Envoltorio del VIH , Morfolinas/farmacología , Naftalenos/farmacología , Dolor/tratamiento farmacológico , Analgesia , Animales , Masculino , Dimensión del Dolor , Sustancia Gris Periacueductal , Ratas Sprague-DawleyRESUMEN
Emerging evidence indicates the involvement of GPR55 and its proposed endogenous ligand, lysophosphatidylinositol (LPI), in nociception, yet their role in central pain processing has not been explored. Using Ca(2+) imaging, we show here that LPI elicits concentration-dependent and GPR55-mediated increases in intracellular Ca(2+) levels in dissociated rat periaqueductal gray (PAG) neurons, which express GPR55 mRNA. This effect is mediated by Ca(2+) release from the endoplasmic reticulum via inositol 1,4,5-trisphosphate receptors and by Ca(2+) entry via P/Q-type of voltage-gated Ca(2+) channels. Moreover, LPI depolarizes PAG neurons and upon intra-PAG microinjection, reduces nociceptive threshold in the hot-plate test. Both these effects are dependent on GPR55 activation, because they are abolished by pretreatment with ML-193 [N-(4-(N-(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide], a selective GPR55 antagonist. Thus, we provide the first pharmacological evidence that GPR55 activation at central levels is pronociceptive, suggesting that interfering with GPR55 signaling in the PAG may promote analgesia.
Asunto(s)
Calcio/metabolismo , Lisofosfolípidos/farmacología , Percepción del Dolor , Sustancia Gris Periacueductal/fisiología , Receptores de Cannabinoides/genética , Receptores de Cannabinoides/metabolismo , Animales , Animales Recién Nacidos , Células Cultivadas , Femenino , Masculino , Potenciales de la Membrana/efectos de los fármacos , Neuronas/fisiología , Ratas , Ratas Sprague-DawleyRESUMEN
The mechanisms of autonomic imbalance and subsequent cardiovascular manifestations in HIV-1-infected patients are poorly understood. We report here that HIV-1 transactivator of transcription (Tat, fragment 1-86) produced a concentration-dependent increase in cytosolic Ca(2+) in cardiac-projecting parasympathetic neurons of nucleus ambiguus retrogradely labeled with rhodamine. Using store-specific pharmacological agents, we identified several mechanisms of the Tat-induced Ca(2+) elevation: 1) lysosomal Ca(2+) mobilization, 2) Ca(2+) release via inositol 1,4,5-trisphosphate-sensitive endoplasmic reticulum pools, and 3) Ca(2+) influx via transient receptor potential vanilloid type 2 (TRPV2) channels. Activation of TRPV2, nonselective cation channels, induced a robust and prolonged neuronal membrane depolarization, thus triggering an additional P/Q-mediated Ca(2+) entry. In vivo microinjection studies indicate a dose-dependent, prolonged bradycardic effect of Tat administration into the nucleus ambiguus of conscious rats, in which neuronal TRPV2 played a major role. Our results support previous studies, indicating that Tat promotes bradycardia and, consequently, may be involved in the QT interval prolongation reported in HIV-infected patients. In the context of an overall HIV-dependent autonomic dysfunction, these Tat-mediated mechanisms may account for the higher prevalence of sudden cardiac death in HIV-1-infected patients compared with general population with similar risk factors. Our results may be particularly relevant in view of the recent findings that significant Tat levels can still be identified in the cerebrospinal fluid of HIV-infected patients with viral load suppression due to efficient antiretroviral therapy.
Asunto(s)
Bradicardia/fisiopatología , Estado de Conciencia/fisiología , Bulbo Raquídeo/efectos de los fármacos , Sistema Nervioso Parasimpático/efectos de los fármacos , Fragmentos de Péptidos , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/farmacología , Animales , Bradicardia/inducido químicamente , Calcio/metabolismo , Modelos Animales de Enfermedad , Retículo Endoplásmico/metabolismo , Femenino , Inositol 1,4,5-Trifosfato/metabolismo , Masculino , Bulbo Raquídeo/metabolismo , Bulbo Raquídeo/fisiopatología , Microinyecciones , Sistema Nervioso Parasimpático/metabolismo , Sistema Nervioso Parasimpático/fisiopatología , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/efectos adversos , Fragmentos de Péptidos/farmacología , Ratas , Ratas Sprague-Dawley , Canales Catiónicos TRPV/fisiología , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/administración & dosificación , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/efectos adversosRESUMEN
BACKGROUND: Recently we found that fever (part of HIV-related wasting) is induced by the action of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (gp120) in the preoptic anterior hypothalamus (POAH). As the opioid system plays a role in the pathogenesis of HIV-1, in the present study we sought to examine the capacity of the opioid system to regulate the febrile response induced by gp120. METHODS: Stainless steel cannulas were stereotactically into the POAH, and a biotelemetry system was used to monitor the body temperature (Tb changes). We examined the in vivo effects of naloxone as well as highly opioid-selective receptor antagonists, on gp120-induced fever. RESULTS: Pretreatment with naloxone or the mu-opioid receptor-selective antagonist, cyclic d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP), significantly delayed the febrile response induced by gp120. In contrast, naltriben (NTB), a selective antagonist for the delta-2 opioid receptor, did not cause any effect on gp120-induced fever. CONCLUSION: These results (1) provide pharmacologic evidence of a functional in vivo interaction between the opioid system and this viral protein in the POAH and (2) show that mu-opioid receptors can regulate gp120-induced fever.
Asunto(s)
Proteína gp120 de Envoltorio del VIH/fisiología , Proteína gp120 de Envoltorio del VIH/toxicidad , Hipotálamo Anterior/metabolismo , Antagonistas de Narcóticos/farmacología , Área Preóptica/metabolismo , Receptores Opioides mu/fisiología , Animales , Fiebre/inducido químicamente , Fiebre/metabolismo , Hipotálamo Anterior/efectos de los fármacos , Masculino , Área Preóptica/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores Opioides mu/antagonistas & inhibidoresRESUMEN
In addition to acting on mineralocorticoid receptors, aldosterone has been recently shown to activate the G protein-coupled oestrogen receptor (GPER) in vascular cells. In light of the newly identified role for GPER in vagal cardiac control, we examined whether or not aldosterone activates GPER in rat nucleus ambiguus. Aldosterone produced a dose-dependent increase in cytosolic Ca(2+) concentration in retrogradely labelled cardiac vagal neurons of nucleus ambiguus; the response was abolished by pretreatment with the GPER antagonist G-36, but was not affected by the mineralocorticoid receptor antagonists, spironolactone and eplerenone. In Ca(2+)-free saline, the response to aldosterone was insensitive to blockade of the Ca(2+) release from lysosomes, while it was reduced by blocking the Ca(2+) release via ryanodine receptors and abolished by blocking the IP3 receptors. Aldosterone induced Ca(2+) influx via P/Q-type Ca(2+) channels, but not via L-type and N-type Ca(2+) channels. Aldosterone induced depolarization of cardiac vagal neurons of nucleus ambiguus that was sensitive to antagonism of GPER but not of mineralocorticoid receptor. in vivo studies, using telemetric measurement of heart rate, indicate that microinjection of aldosterone into the nucleus ambiguus produced a dose-dependent bradycardia in conscious, freely moving rats. Aldosterone-induced bradycardia was blocked by the GPER antagonist, but not by the mineralocorticoid receptor antagonists. In summary, we report for the first time that aldosterone decreases heart rate by activating GPER in cardiac vagal neurons of nucleus ambiguus.
Asunto(s)
Aldosterona/farmacología , Corazón/fisiología , Receptores de Estrógenos/metabolismo , Nervio Vago/fisiología , Potenciales de Acción , Animales , Calcio/metabolismo , Señalización del Calcio , Células Cultivadas , Corazón/efectos de los fármacos , Corazón/inervación , Frecuencia Cardíaca , Masculino , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/fisiología , Ratas , Ratas Sprague-Dawley , Receptores de Estrógenos/antagonistas & inhibidores , Receptores de Mineralocorticoides/metabolismo , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Nervio Vago/efectos de los fármacos , Nervio Vago/metabolismoRESUMEN
Nesfatin-1, a peptide whose receptor is yet to be identified, has been involved in the modulation of feeding, stress, and metabolic responses. More recently, increasing evidence supports a modulatory role for nesfatin-1 in autonomic and cardiovascular activity. This study was undertaken to test if the expression of nesfatin-1 in the nucleus ambiguus, a key site for parasympathetic cardiac control, may be correlated with a functional role. As we have previously demonstrated that nesfatin-1 elicits Ca²âº signaling in hypothalamic neurons, we first assessed the effect of this peptide on cytosolic Ca²âº in cardiac pre-ganglionic neurons of nucleus ambiguus. We provide evidence that nesfatin-1 increases cytosolic Ca²âº concentration via a Gi/o-coupled mechanism. The nesfatin-1-induced Ca²âº rise is critically dependent on Ca²âº influx via P/Q-type voltage-activated Ca²âº channels. Repeated administration of nesfatin-1 leads to tachyphylaxis. Furthermore, nesfatin-1 produces a dose-dependent depolarization of cardiac vagal neurons via a Gi/o-coupled mechanism. In vivo studies, using telemetric and tail-cuff monitoring of heart rate and blood pressure, indicate that microinjection of nesfatin-1 into the nucleus ambiguus produces bradycardia not accompanied by a change in blood pressure in conscious rats. Taken together, our results identify for the first time that nesfatin-1 decreases heart rate by activating cardiac vagal neurons of nucleus ambiguus. Our results indicate that nesfatin-1, one of the most potent feeding peptides, increases cytosolic Ca²âº by promoting Ca²âº influx via P/Q channels and depolarizes nucleus ambiguus neurons; both effects are Gi/o-mediated. In vivo studies indicate that microinjection of nesfatin-1 into nucleus ambiguus produces bradycardia in conscious rats. This is the first report that nesfatin-1 increases the parasympathetic cardiac tone.
Asunto(s)
Bradicardia/inducido químicamente , Proteínas de Unión al Calcio/farmacología , Proteínas de Unión al ADN/farmacología , Corazón/efectos de los fármacos , Corazón/inervación , Bulbo Raquídeo/efectos de los fármacos , Proteínas del Tejido Nervioso/farmacología , Neuronas/efectos de los fármacos , Nervio Vago/efectos de los fármacos , Animales , Animales Recién Nacidos , Presión Sanguínea/efectos de los fármacos , Bradicardia/fisiopatología , Calcio/metabolismo , Canales de Calcio Tipo P/efectos de los fármacos , Canales de Calcio Tipo Q/efectos de los fármacos , Proteínas de Unión al Calcio/administración & dosificación , Células Cultivadas , Proteínas de Unión al ADN/administración & dosificación , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Bulbo Raquídeo/citología , Potenciales de la Membrana/efectos de los fármacos , Microinyecciones , Proteínas del Tejido Nervioso/administración & dosificación , Nucleobindinas , Ratas , Ratas Sprague-Dawley , Receptores Acoplados a Proteínas G/fisiología , Taquifilaxis/fisiología , Telemetría , Nervio Vago/citologíaRESUMEN
UNLABELLED: Human and animal studies suggest that estrogens are involved in the processing of nociceptive sensory information and analgesic responses in the central nervous system. Rapid pronociceptive estrogenic effects have been reported, some of which likely involve G protein-coupled estrogen receptor (GPER) activation. Membrane depolarization and increases in cytosolic calcium and reactive oxygen species (ROS) levels are markers of neuronal activation, underlying pain sensitization in the spinal cord. Using behavioral, electrophysiological, and fluorescent imaging studies, we evaluated GPER involvement in spinal nociceptive processing. Intrathecal challenging of mice with the GPER agonist G-1 results in pain-related behaviors. GPER antagonism with G15 reduces the G-1-induced response. Electrophysiological recordings from superficial dorsal horn neurons indicate neuronal membrane depolarization with G-1 application, which is G15 sensitive. In cultured spinal sensory neurons, G-1 increases intracellular calcium concentration and induces mitochondrial and cytosolic ROS accumulation. In the presence of G15, G-1 does not elicit the calcium and ROS responses, confirming specific GPER involvement in this process. Cytosolic calcium concentration elevates faster and with higher amplitude following G-1 intracellular microinjections compared to extracellular exposure, suggesting subcellular GPER functionality. Thus, GPER activation results in spinal nociception, and the downstream mechanisms involve cytosolic calcium increase, ROS accumulation, and neuronal membrane depolarization. PERSPECTIVE: Our results suggest that GPER modulates pain processing in spinal sensory neurons via cytosolic calcium increase and ROS accumulation. These findings extend the current knowledge on GPER involvement in physiology and disease, providing the first evidence of its pronociceptive effects at central levels and characterizing some of the underlying mechanisms.
Asunto(s)
Nocicepción/fisiología , Dolor Nociceptivo/metabolismo , Receptores de Estrógenos/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Médula Espinal/patología , Potenciales de Acción/efectos de los fármacos , Analgésicos Opioides/administración & dosificación , Animales , Animales Recién Nacidos , Conducta Animal/efectos de los fármacos , Benzodioxoles/administración & dosificación , Calcio/metabolismo , Células Cultivadas , Ciclopentanos/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Técnicas In Vitro , Masculino , Ratones , Ratones Endogámicos ICR , Microinyecciones , Morfina/administración & dosificación , Neuronas/efectos de los fármacos , Neuronas/fisiología , Nocicepción/efectos de los fármacos , Dolor Nociceptivo/tratamiento farmacológico , Dolor Nociceptivo/patología , Dimensión del Dolor , Técnicas de Placa-Clamp , Quinolinas/administración & dosificación , Quinolinas/farmacología , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Receptores de Estrógenos/antagonistas & inhibidores , Receptores de Estrógenos/genética , Receptores Acoplados a Proteínas G/genética , Médula Espinal/citología , Superóxidos/metabolismoRESUMEN
BACKGROUND: Buprenorphine is an opioid receptor ligand whose mechanism of action is incompletely understood. METHODS: Using Ca(2+) imaging, we assessed the effects of buprenorphine, ß-endorphin, and morphine on cytosolic Ca(2+) concentration [Ca(2+)](i), in rat striatal neurons. RESULTS: Buprenorphine (0.01-1 µM) increased [Ca(2+)](i) in a dose-dependent manner in a subpopulation of rat striatal neurons. The effect of buprenorphine was largely reduced by naloxone, a non-selective opioid receptor antagonist, but not by µ, κ, δ or NOP-selective antagonists. ß-Endorphin (0.1 µM) increased [Ca(2+)](i) with a lower amplitude and slower time course than buprenorphine. Similar to buprenorphine, the effect of ß-endorphin was markedly decreased by naloxone, but not by opioid-selective antagonists. Morphine (0.1-10 µM), did not affect [Ca(2+)](i) in striatal neurons. CONCLUSIONS: Our results suggest that buprenorphine and ß-endorphin act on a distinct type/subtype of plasmalemmal opioid receptors or activate intracellular opioid-like receptor(s) in rat striatal neurons.
Asunto(s)
Buprenorfina/farmacología , Calcio/metabolismo , Cuerpo Estriado/metabolismo , Citosol/metabolismo , Narcóticos/farmacología , Neuronas/metabolismo , Receptores Opioides/agonistas , Animales , Cuerpo Estriado/citología , Cuerpo Estriado/efectos de los fármacos , Citosol/efectos de los fármacos , Colorantes Fluorescentes , Fura-2 , Ligandos , Morfina/farmacología , Naltrexona/análogos & derivados , Naltrexona/farmacología , Antagonistas de Narcóticos/farmacología , Neuronas/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , betaendorfina/farmacologíaRESUMEN
Cannabinoid and opioid drugs produce marked changes in body temperature. Recent findings have extended our knowledge about the thermoregulatory effects of cannabinoids and opioids, particularly as related to delta opioid receptors, endogenous systems, and transient receptor potential (TRP) channels. Although delta opioid receptors were originally thought to play only a minor role in thermoregulation compared to mu and kappa opioid receptors, their activation has been shown to produce hypothermia in multiple species. Endogenous opioids and cannabinoids also regulate body temperature. Mu and kappa opioid receptors are thought to be in tonic balance, with mu and kappa receptor activation producing hyperthermia and hypothermia, respectively. A particularly intense research focus is TRP channels, where TRPV1 channel activation produces hypothermia whereas TRPA1 and TRPM8 channel activation causes hyperthermia. The marked hyperthermia produced by TRPV1 channel antagonists suggests these warm channels tonically control body temperature. A better understanding of the roles of cannabinoid, opioid, and TRP systems in thermoregulation may have broad clinical implications and provide insights into interactions among neurotransmitter systems involved in thermoregulation.
Asunto(s)
Analgésicos Opioides/farmacología , Regulación de la Temperatura Corporal/fisiología , Temperatura Corporal/efectos de los fármacos , Cannabinoides/farmacología , Hipotermia/metabolismo , Receptores de Cannabinoides/metabolismo , Receptores Opioides/metabolismo , Receptores sigma/metabolismo , Animales , Benzaldehídos/farmacología , Temperatura Corporal/fisiología , Cannabinoides/agonistas , Humanos , Hipotermia/etiologíaRESUMEN
Recently, we have shown that morphine's analgesic activity can be attenuated by chemokines, specifically CCL5 and CXCL12. Because the HIV-1 coat protein, glycoprotein 120 (gp120), binds to the same receptors as do CCL5 and CXCL12, experiments were designed to investigate the effect of gp120 in the brain on antinociception induced by morphine in the cold-water (-3°C) tail-flick (CWT) and hot-plate (+54°C) tests. In addition, mu-opioid-receptor-mediated effects in brain periaqueductal grey (PAG) slices were examined with whole-cell patch-clamp recordings. The results showed that (1) pretreatment with gp120 itself (10, 25, 50, 100 or 133 ng, PAG) had no nociceptive effect in the CWT; (2) pretreatment with gp120 (25 or 100 ng) dose-dependently reduced antinociception induced by subcutaneous (sc) injection of morphine (3 or 6 mg/kg) or PAG injection of morphine (100 ng) in the CWT; (3) a PAG injection of gp120 (133 ng), given 30 min before sc injection of morphine (6 mg/kg), similarly reduced morphine antinociception in the hot-plate test; (4) the inhibitory effect of gp120 on morphine-induced antinociception in the CWT was reversed by AMD3100, an antagonist of CXCR4; (5) pretreatment of slices with gp120 (200 pM) prevented morphine (10 µM)-induced hyperpolarization and reduction of input resistance in PAG neurons. Electrophysiology studies paralleled gp120-induced desensitization of a mu-opioid-receptor-mediated response in PAG neurons at the single-cell level. These studies are the first to demonstrate that the analgesic activity of morphine can be reduced by the presence of gp120 in the PAG and that pretreatment with AMD3100 is able to restore the analgesic effects of morphine.
Asunto(s)
Analgésicos Opioides/farmacología , Proteína gp120 de Envoltorio del VIH/farmacología , Morfina/farmacología , Dimensión del Dolor/efectos de los fármacos , Percepción del Dolor/efectos de los fármacos , Analgesia , Animales , Conducta Animal/efectos de los fármacos , Bencilaminas , Frío , Ciclamas , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Compuestos Heterocíclicos/farmacología , Calor , Masculino , Potenciales de la Membrana/efectos de los fármacos , Sustancia Gris Periacueductal/efectos de los fármacos , Sustancia Gris Periacueductal/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores CXCR4/antagonistas & inhibidores , Receptores Opioides mu/metabolismoRESUMEN
BACKGROUND: We showed recently that elevated brain levels of the chemokine stromal cell-derived growth factor-1α (SDF-1α/CXCL12, a ligand for the human immunodeficiency virus [HIV] co-receptor CXCR4) diminish the antinociceptive effect of morphine, but failed to influence buprenorphine-induced antinociception. AIMS: Because the HIV-1 coat protein, glycoprotein 120 (gp120) T-tropic strain, binds to the same receptor as SDF-1α/CXCL12, the present experiments were designed to investigate the consequence of administering gp120 to rat brain on buprenorphine-induced antinociception in the 54°C hot plate test. For comparative purposes, the effect of gp120 on an equi-antinociceptive dose of methadone was also examined. METHODS: A sterilized stainless-steel C313G guide cannula was implanted into the periaqueductal grey (PAG), a brain region critical for the processing of pain signals, and a primary site of action of many analgesics. Rats were pretreated with gp120, administered into the PAG. RESULTS: The subsequent antinociception associated with methadone was diminished whereas buprenorphine-induced antinociception was unaffected. Buprenorphine thus appears to be a more effective analgesic than methadone in the presence of gp120 in the brain, a condition that is associated with HIV-related pain and infection.